Fluoride Treatment and Risk of Fracture In Osteoporosis Patients

dc.contributor.author	Alshikhi, Sara Almabrouk
dc.date.accessioned	2018-05-21T14:28:36Z
dc.date.available	2018-05-21T14:28:36Z
dc.date.issued	2018-03-14
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/275
dc.description	Osteoporosis is common systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and a consequent increase in fracture risk” • More common in postmenopausal Sodium fluoride stimulates bone formation and increases cancellous-bone mass Sodium fluoride (NaF) was currently the only pharmacological agent capable of stimulating bone formation through a direct effect on the osteoblast	en_US
dc.language.iso	en	en_US
dc.publisher	faculty of Basic Medical Science - Libyan International Medical University	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Fluoride Treatment and Risk of Fracture In Osteoporosis Patients	en_US
dc.type	Other	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States